Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

e sample sizes were too small to draw firm conclusions.

About the SPIRIT III Trial

SPIRIT III is a prospective, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669 XIENCE V patients, 333 TAXUS patients) with either one or two de novo coronary artery lesions. The trial was conducted across 65 academic and community-based centers in the United States between June 22, 2005, and March 15, 2006.

The primary endpoint of the SPIRIT III trial was in-segment late loss at eight months, wherein XIENCE V demonstrated superiority to TAXUS with a statistically superior 50 percent reduction in late loss (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS, p-value =0.004). In-segment late loss is a measure of vessel re-narrowing.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION((R)) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

Abbott's market-leading XIENCE V drug eluting stent is commercially available in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmace
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ended ... a 10 percent increase compared to the quarter ended December ... basis). Net income was $91.2 million, an increase of 5 ... earnings per share for the quarter were $0.64, an increase ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... WASHINGTON, Feb. 28, 2012 DIA and the ... Comparative Effectiveness: A Real-World User,s Guide  Conference on ... Washington, D.C. The conference will focus on the ... comparative effectiveness research (CER) applied within health technology ...
... Varian Medical Systems (NYSE: VAR ) ... Drug Administration (FDA) for a surface beacon transponder to ... real-time tracking device capable of monitoring motion during radiotherapy ... Beacon® Transponder is placed temporarily on the skin for ...
Cached Medicine Technology:DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research 2Varian Medical Systems Receives FDA 510(k) Clearance for Use of Transponder to Monitor Motion During Radiotherapy Anywhere in Body 2
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Lower-Auto-Insurance.com has released a new blog ... a car for reducing the costs of an auto insurance ... be able to get lower prices for their vehicle insurance policies. ... role in determining policy costs. Because of this, drivers should ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Systems, Inc. (MDS), a national leader in accounts receivable management, and ... to the newly created position of Chief Operating Officer (COO). ... ... healthcare receivables industry leader, MDS ( www.meddatsys.com ), has announced Eugene ...
... House made the correct decision to withdraw its ... have military veterans, personal insurance companies pay for ... Ryan, Jr., USN-Ret., president of the Military Officers ... President Obama that "pursuing this insurance proposal would ...
... - Estimated one-year, recurrence-free survival was 98% for Kit-positive ... placebo(1)- Historically, one in two patients experienced recurrence of ... - Gleevec is the only treatment in the US ... GIST after surgery; regulatory review is underway in the ...
... ANN ARBOR, Mich.---Scientists are closer to understanding which proteins ... exercise. This understanding could lead to new drug therapies ... and other health problems associated with having high blood ... by the body doesn,t properly stimulate the transport of ...
... 18 Askesis Development Group, Inc., a leader ... treatment, and social services markets, is pleased to ... enhanced features are focused on creating a completely ... comprehensive electronic medical record (EMR), and streamlined revenue ...
... 18 Bionovo, Inc. (Nasdaq: BNVI ), a ... in women,s health and oncology, today announced that Isaac Cohen, ... Wall Street Analyst Forum,s 20th Annual Institutional Investor Conference at ... will be held at the University Club in New York ...
Cached Medicine News:Health News:Medical Data Systems, Inc. (MDS) Announces New Chief Operating Officer (COO) 2Health News:Medical Data Systems, Inc. (MDS) Announces New Chief Operating Officer (COO) 3Health News:White House Makes Correct Decision On Veterans Insurance Proposal 2Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 2Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 3Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 4Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 5Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 6Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 7Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 8Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 9Health News:Scientists closer to understanding how to control high blood sugar 2Health News:Askesis Development Group, Inc. Launches New Behavioral Health Software for Electronic Medical Records (EMR) and Practice Management 2Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 2Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 3Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 4
... The new MyiQ real-time PCR detection system ... of common green fluorescent dyes such as ... interfaces directly with the iCycler thermal cycler, ... and Peltier-effect driven performance. The MyiQ real-time ...
... The SmartCycler System is a rapid, ... from prepared biological samples. By automating much ... reaction site individually programmable, it is the ... system now on the market. The SmartCycler ...
Inquire...
Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile...
Medicine Products: